Phase 2 trial of ibudilast in progressive multiple sclerosis

R. J. Fox, C. S. Coffey, R. Conwit, M. E. Cudkowicz, T. Gleason, A. Goodman, E. C. Klawiter, K. Matsuda, M. McGovern, R. T. Naismith, A. Ashokkumar, J. Barnes, D. Ecklund, E. Klingner, M. Koepp, J. D. Long, S. Natarajan, B. Thornell, J. Yankey, R. A. BermelJ. P. Debbins, X. Huang, P. Jagodnik, M. J. Lowe, K. Nakamura, S. Narayanan, K. E. Sakaie, B. Thoomukuntla, X. Zhou, S. Krieger, E. Alvarez, M. Apperson, K. Bashir, B. A. Cohen, P. K. Coyle, S. Delgado, L. D. Dewitt, A. Flores, B. S. Giesser, M. D. Goldman, B. Jubelt, N. Lava, S. G. Lynch, H. Moses, D. Ontaneda, J. S. Perumal, M. Racke, P. Repovic, C. S. Riley, C. Severson, S. Shinnar, V. Suski, B. Weinstock-Guttman, V. Yadav, A. Zabeti

Research output: Contribution to journalArticlepeer-review

189 Scopus citations


BACKGROUND There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis. METHODS We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (=100 mg daily) or placebo for 96 weeks. The primary efficacy end point was the rate of brain atrophy, as measured by the brain parenchymal fraction (brain size relative to the volume of the outer surface contour of the brain). Major secondary end points included the change in the pyramidal tracts on diffusion tensor imaging, the magnetization transfer ratio in normal-appearing brain tissue, the thickness of the retinal nerve-fiber layer, and cortical atrophy, all measures of tissue damage in multiple sclerosis. RESULTS Of 255 patients who underwent randomization, 129 were assigned to ibudilast and 126 to placebo. A total of 53% of the patients in the ibudilast group and 52% of those in the placebo group had primary progressive disease; the others had secondary progressive disease. The rate of change in the brain parenchymal fraction was -0.0010 per year with ibudilast and -0.0019 per year with placebo (difference, 0.0009; 95% confidence interval, 0.00004 to 0.0017; P = 0.04), which represents approximately 2.5 ml less brain-tissue loss with ibudilast over a period of 96 weeks. Adverse events with ibudilast included gastrointestinal symptoms, headache, and depression. CONCLUSIONS In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression. (Funded by the National Institute of Neurological Disorders and Stroke and others; NN102/SPRINT-MS number, NCT01982942.)

Original languageEnglish (US)
Pages (from-to)846-855
Number of pages10
JournalNew England Journal of Medicine
Issue number9
StatePublished - Aug 30 2018

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Phase 2 trial of ibudilast in progressive multiple sclerosis'. Together they form a unique fingerprint.

Cite this